Hirschsprung's disease: Current management and prospects for transplantation of enteric nervous system progenitor cells
Introduction
Hirschsprung's disease (HSCR) results from a congenital absence of ganglion cells (aganglionosis) in a variable part of the distal gut and affected children usually present shortly after birth with symptoms and signs of distal bowel obstruction. It affects 1 in 5000 newborns in Europe, Asia and North America although the incidence can be significantly higher in communities with a homogeneous genetic background such as the Mennonites [1]. Typical operative findings are of an apparently normal distal rectum and a massively dilated proximal colon. Such findings led early investigators to assume that the dilated bowel was diseased. It was over 60 years following Hirschsprung's first description of the disease in 1887 before the absence of ganglion cells in the apparently normal distal rectum was recognized as the cause of the disease.
These ganglion cells are cell bodies of neurons belonging to a major subset of the autonomic nervous system, the enteric nervous system (ENS), and are found in the myenteric and submucosal plexus of the large bowel. The ENS is vast, containing a similar number of neurons to that in the central nervous system (CNS) and neurons release a diverse range of neurotransmitters. The complex process of mixing and propulsion of gut contents through the digestive tract is a result of interactions between several components of the bowel wall—the enteric nervous system, gut ‘pacemaker’ cells (known as interstitial cells of Cajal), and circular and longitudinal smooth muscle [2]. The ENS is also involved in fluid and electrolyte balance and gut immunity. An analogy to this system is that the ENS can be likened to the conductor; the other components are the orchestra. The ENS itself is subject to afferent inputs from the CNS that can modulate gut motility. Aganglionosis results in an uncoordinated tonic state in the affected gut segment resulting in the clinical presentation of bowel obstruction as luminal contents fail to progress. A variable length of bowel can be affected—in over 80% of cases the aganglionosis is restricted to the internal sphincter, rectum and a few centimeters of sigmoid colon and is termed short segment disease. Less commonly a more extensive length of distal bowel is affected causing long segment or total colonic disease. Total intestinal aganglionosis is a rare and serious form of the disease for which small bowel transplantation may be the only effective form of treatment. A serious complication of HSCR is enterocolitis, the causes of which are multifactorial but which can be life-threatening.
Section snippets
Surgery for Hirschsprung's disease
The first effective surgery for Hirschsprung's disease was performed by Olvar Swenson in 1948 and the principles of this operation still apply: resection of the distal aganglionic bowel and a low anastomosis of ganglionic bowel to the rectum. Various modifications of this surgery have been described, largely technical modifications to avoid anastomotic complications or the requirement for extensive pelvic dissection (Table 1). Long-term outcome data suggests no clear advantage of any particular
Outcomes of surgery
There are increasing data on long-term outcomes from Hirschsprung's surgery although it should be borne in mind that the oldest recipients of the earliest ‘pull-through’ procedures are only in their 6th decade. Clinicians are now assessing the outcomes of procedures that are now no longer performed in the same way. The long-term outcomes of current management approaches are obviously a matter of conjecture. There has been a huge variation in methodologies employed when assessing outcomes for
Stem cells, genes and the origins of Hirschsprung's disease
The ENS is principally derived from the embryonic vagal neural crest [6] although a small sacral component has also been identified. During the first trimester, cells migrate through the oesophagus and down the developing gut in a rostro-caudal direction. Through a process of migration, cell division and differentiation the entire gut is colonized with neurons and glia with the distal colon, rectum and internal sphincter being the last to be colonized. Cells migrate through the embryonic bowel
Developing a stem cell based therapy for HSCR
We have seen that current surgical strategies are failing a significant proportion of children with HSCR. Advances in developmental biology have led to the discovery that ENSC are present in the postnatal human gut [10], [15] has led to the hope that these cells could be used autologously to colonize the aganglionic bowel in children with HSCR as a primary or adjunctive treatment. Furthermore, multipotent stem cells could potentially be isolated from the CNS [16] or bone marrow derived
References (20)
- et al.
Transanal versus open endorectal pull-through for Hirschsprung's disease
J Pediatr Surg
(2000) - et al.
Are the long-term results of the transanal pull-through equal to those of the transabdominal pull-through? A comparison of the 2 approaches for Hirschsprung disease
J Pediatr Surg
(2007) - et al.
Localization and endothelin-3 dependence of stem cells of the enteric nervous system in the embryonic colon
J Pediatr Surg
(2002) - et al.
Enteric nervous system progenitors are coordinately controlled by the G protein-coupled receptor EDNRB and the receptor tyrosine kinase RET
Neuron
(2003) - et al.
Cell-intrinsic differences between stem cells from different regions of the peripheral nervous system regulate the generation of neural diversity
Neuron
(2002) - et al.
Neural crest stem cells persist in the adult gut but undergo changes in self-renewal, neuronal subtype potential, and factor responsiveness
Neuron
(2002) - et al.
Transplantation of mammalian olfactory progenitors into chick hosts reveals migration and differentiation potentials dependent on cell commitment
Mol Cell Neurosci
(2001) - et al.
Neuro-glial differentiation of human bone marrow stem cells in vitro
Exp Neurol
(2005) - et al.
Neural stem cells express RET, produce nitric oxide, and survive transplantation in the gastrointestinal tract
Gastroenterol
(2001) - et al.
Hirschsprung disease, associated syndromes and genetics: a review
J Med Genet
(2008)
Cited by (13)
New mutations associated with Hirschsprung disease
2020, Anales de PediatriaHirschsprung's Disease
2013, Brenner's Encyclopedia of Genetics: Second EditionDevelopment of the enteric nervous system and its role in intestinal motility during fetal and early postnatal stages
2009, Seminars in Pediatric SurgeryCitation Excerpt :However, all the known mutations account for less than 50% of HSCR cases, suggesting that some mutations may involve noncoding regulatory regions of known genes.43 Although the current curative treatment for HSCR is surgery, there is a rapidly expanding field endeavoring to develop a stem cell therapy for this disorder, the aim being to replace the missing ENS cells in the distal gut with stem cells derived from gut or other sources.15,44-47 Such stem cells, when transplanted to the gut, would subsequently differentiate into neurons and thus functionally innervate the affected gut segment and restore gut function.
Practical pathology and genetics of Hirschsprung's disease
2009, Seminars in Pediatric SurgeryCitation Excerpt :Given the genetic and phenotypic heterogeneity in HSCR, multiinstitutional studies with standardized molecular genetic and pathologic protocols may be required to derive meaningful conclusions in a reasonable time period. Stem cell therapy for HSCR has engendered some enthusiasm as a potential treatment for HSCR.85 The hypothesis has been advanced that function of the aganglionic bowel might be restored by neurons that differentiate from autologous or heterologous neural stem cells.
Anatomicalcolonic malformation with enteric nervous system abnormalities in allied disorders of Hirschsprung's disease
2020, Chinese Journal of Pediatric SurgeryCo-culture of neuroepithelial stem cells with interstitial cells of Cajal results in neuron differentiation
2015, International Journal of Clinical and Experimental Medicine
- 1
Tel.: +44 151 794 5474; fax: +44 151 794 5517.